Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now full pipeline small index

B Lymphoblastic Lymphoma: full-pipeline trial registry

3 of 5 indexed B Lymphoblastic Lymphoma trials are currently recruiting.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count

B Lymphoblastic Lymphoma: 5 US clinical trials tracked, 3 recruiting.

B Lymphoblastic Lymphoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Alliance for Clinical Trials in Oncology, running 1 of these trials.

Enrollment posture brief

Registry condition b-lymphoblastic-lymphoma

OPEN 3 | RECR 60% | LATE 2 | EARLY 2 | RANK #3391 | SPON 1

Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%B Lymphoblastic Lymphoma (th…60%
Open-enrollment share among volume-matched conditions near B Lymphoblastic Lymphoma

B Lymphoblastic Lymphoma lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for B Lymphoblastic Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. B Lymphoblastic Lymphoma is recruiting above its size-band peers.

    3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates B Lymphoblastic Lymphoma research.

    Alliance for Clinical Trials in Oncology accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most B Lymphoblastic Lymphoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 80 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.

  4. B Lymphoblastic Lymphoma research is mostly interventional.

    5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 22Phase 32

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 2

Named interventions

Most-linked intervention names on B Lymphoblastic Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Blinatumomab Biological
3 trials
Dexamethasone Drug
3 trials
Cyclophosphamide Drug
3 trials
Cytarabine Drug
2 trials
Biospecimen Collection Procedure
2 trials
Packed Red Blood Cell Transfusion Other
1 trials
Activity Tracking Other
1 trials
Methotrexate Drug
1 trials

US sites by state

Facility locations filed on B Lymphoblastic Lymphoma trials. A trial with sites in several states counts in each.

California 3 trials
Alabama 3 trials
Arizona 2 trials
Arkansas 2 trials
Alaska 2 trials
Washington 1 trials
Texas 1 trials
Illinois 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this B Lymphoblastic Lymphoma page

5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This B Lymphoblastic Lymphoma condition card totals 5 registered trials; most-linked intervention Blinatumomab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.